9,796 reports of this reaction
6.5% of all DULAGLUTIDE reports
#2 most reported adverse reaction
INJECTION SITE PAIN is the #2 most commonly reported adverse reaction for DULAGLUTIDE, manufactured by Eli Lilly and Company. There are 9,796 FDA adverse event reports linking DULAGLUTIDE to INJECTION SITE PAIN. This represents approximately 6.5% of all 151,183 adverse event reports for this drug.
Patients taking DULAGLUTIDE who experience injection site pain should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INJECTION SITE PAIN is moderately reported among DULAGLUTIDE users, representing a notable but not dominant share of adverse events.
In addition to injection site pain, the following adverse reactions have been reported for DULAGLUTIDE:
The following drugs have also been linked to injection site pain in FDA adverse event reports:
INJECTION SITE PAIN has been reported as an adverse event in 9,796 FDA reports for DULAGLUTIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
INJECTION SITE PAIN accounts for approximately 6.5% of all adverse event reports for DULAGLUTIDE, making it one of the most commonly reported side effect.
If you experience injection site pain while taking DULAGLUTIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.